PROCEPT BioRobotics Reports Q1 2026 Revenue of $83.1M, Up 20% YoY; Net Loss Widens to $31.6M

PROCEPT BioRobotics Corp

2026-Q1 EPS reported -$0.56 revenue$83,132,000

Total revenue $83.1M, +20% YoY; U.S. procedures 12,200, +30% YoY.
Sold 49 U.S. Hydros systems, ASP ~$485,000; U.S. install base 765 systems, +40% YoY.
FDA clearance of second-generation FirstAssist AI software for Aquablation therapy.
Full-year 2026 revenue guidance $390M-$410M, growth 27%-33%; adjusted EBITDA loss outlook $30M-$17M.
Net loss $31.6M vs $24.7M in prior year; adjusted EBITDA loss $18.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROCEPT BioRobotics Corp reported the quarter ended March 31, 2026 results: revenue $83.1 million, net income Net loss was $31.6 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: $83.1 million
Net income: Net loss was $31.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing." Wood continued: “Aquablation® users completed approximately 12,200 U.S. procedures in the first quarter of

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

PROCEPT BioRobotics Corp filing history →

Source: SEC EDGAR

accession 0001588978-26-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.